San Diego, CA -- (SBWIRE) -- 02/18/2016 -- An investigation for shareholders in NASDAQ:OMED shares over potential securities laws violations by Oncomed Pharmaceuticals and certain of its directors and officers was announced.

Investors who purchased shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) concerning whether a series of statements by Oncomed Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On January 25, 2016 Oncomed Pharmaceuticals Inc (NASDAQ:OMED) announced an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB). The DSMB assessed data from 172 patients treated as of a January 6, 2016 data cutoff date. Shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) declined to as low as $8.42 per share on February 12, 2016.

On February 17, 2016, NASDAQ:OMED shares closed at $9.75 per share.

Those who purchased shares of Oncomed Pharmaceuticals Inc (NASDAQ:OMED) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com